Send to

Choose Destination
Parkinsonism Relat Disord. 2013 Oct;19(10):851-8. doi: 10.1016/j.parkreldis.2013.06.008. Epub 2013 Jul 22.

The diagnostic utility of cerebrospinal fluid alpha-synuclein analysis in dementia with Lewy bodies - a systematic review and meta-analysis.

Author information

College of Medicine and Veterinary Medicine, University of Edinburgh, UK.



Dementia with Lewy Bodies (DLB) can be difficult to distinguish clinically from other dementias.


To investigate the diagnostic utility of CSF alpha-synuclein in differentiating between DLB and other dementias.


Electronic databases were systematically searched for studies investigating reproducible alpha synuclein quantification methods. Random effects model was used to calculate weighted mean difference (WMD) and 95% confidence intervals between DLB and other groups.


A total of 13 studies, comprising 2728 patients were included. Mean CSF alpha-synuclein concentration was significantly lower in DLB patients compared to those with Alzheimers disease (AD) [WMD -0.24; 95% CI, -0.45, -0.03; p = 0.02]. No significant difference was found between patients with DLB compared to Parkinsons disease [WMD 0.05; 95% CI, -0.17, 0.28; p = 0.65] or other neurodegenerative conditions.


CSF alpha synuclein may be of diagnostic use in differentiating between DLB and AD. We propose several recommendations to guide better design of future studies.


Alpha-synuclein; Biomarker; Cerebrospinal fluid; Dementia; Dementia with Lewy bodies

[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Elsevier Science
Loading ...
Support Center